Keep Factually independent
Whether you agree or disagree with our analysis, these conversations matter for democracy. We don't take money from political groups - even a $5 donation helps us keep it that way.
What is the incidence and prognosis of rare events like Guillain-Barré syndrome, transverse myelitis, and Bell’s palsy after Moderna shots?
Executive summary
Large surveillance studies and public databases find that Guillain‑Barré syndrome (GBS), transverse myelitis (TM) and Bell’s palsy after Moderna’s mRNA-1273 shots are reported but remain rare compared with overall doses given; CDC analyses found increased GBS risk after the Janssen adenoviral vaccine but not after Moderna or Pfizer [1] [2]. Case reports and pharmacovigilance reviews document individual TM and GBS events after Moderna doses and multiple Bell’s palsy reports in trials and post‑marketing surveillance, with most Bell’s palsy cases resolving over weeks to months [3] [4] [5] [6].
1. What the large safety systems found: low signal for GBS with Moderna, signal for Janssen
The Vaccine Safety Datalink and CDC analyses covering millions of vaccinees showed a measurable increased risk of Guillain‑Barré syndrome after the Ad26.COV2.S (Janssen) product but did not find increased risk after mRNA vaccines, including Moderna’s mRNA‑1273 [2] [1]. Multiple summaries of VSD/VAERS data and cohort studies therefore treat GBS after Moderna as within background expectations rather than a confirmed vaccine‑specific excess [7] [1].
2. Case reports and case series: rare but real—GBS and TM after Moderna have been published
Clinicians have published individual GBS case reports occurring within days to weeks after Moderna vaccination; those reports emphasize temporality and call for vigilance while noting that causality is not proven by single cases [3] [8] [9]. Similarly, longitudinally extensive transverse myelitis and other acute TM presentations after Moderna have been described in case reports and series; authors stress the rarity of TM and the difficulty of proving a causal link in single patients [4] [10] [11].
3. Pharmacovigilance and aggregated TM data: mixed signals and low absolute counts
Global safety‑database analyses (VigiBase, VAERS summaries) identified TM reports across vaccine types; one pharmacoepidemiological review found 500 TM reports to WHO databases with 17% after Moderna (mRNA‑1273), but authors caution that disproportionality signals do not establish causality and that TM is rare [12]. Earlier VAERS tallies showed small absolute counts (for example, nine TM cases among >51 million vaccinations reported to the American Neurological Association at one point) and epidemiologists note TM’s baseline incidence of roughly 1–8 per million per year, so distinguishing coincidence from causation requires formal epidemiologic methods [13] [14].
4. Bell’s palsy: trial imbalance, many post‑marketing case reports, generally good recovery
Moderna’s pivotal trial noted three Bell’s palsy events in vaccine recipients and one in placebo; regulators recommended post‑marketing surveillance [15] [16]. Subsequent systematic reviews collected multiple case reports attributed to both Pfizer and Moderna, and population studies show mixed findings—some analyses conclude rates align with background incidence while others detect small excesses depending on method and vaccine studied [17] [5] [6]. Clinically, Bell’s palsy after vaccination has most often been transient and treatable; The Lancet notes over 90% of Bell’s palsy cases (not vaccine‑specific) recover within nine months with early corticosteroid treatment [6].
5. Prognosis if one of these events occurs after vaccination
Case reports and clinical reviews show that recognized GBS and TM require prompt neurological workup and often inpatient therapy (IVIG, plasmapheresis, steroids as appropriate), and outcomes vary: many GBS patients improve with therapy though some have prolonged disability; TM outcomes range from full recovery to persistent deficits depending on severity and extent [18] [10]. Bell’s palsy following COVID‑19 vaccines has most often been self‑limited with many patients recovering in weeks to months [6] [19].
6. How to interpret risk: absolute numbers, background rates, and surveillance limits
Available surveillance shows small absolute counts amid hundreds of millions of doses; the CDC emphasizes Janssen‑GBS as a distinct signal while concluding no increased GBS risk with Moderna [1] [2]. Pharmacovigilance signals (disproportionality in databases) reflect reporting and cannot by themselves prove causation; dedicated epidemiologic studies with denominator data are needed to estimate true incidence beyond case reports [12] [2].
7. What questions remain and how experts advise clinicians and patients
Authors of case reports and reviews uniformly call for continued surveillance, rapid reporting to systems like VAERS and VigiBase, and high clinical vigilance for neurologic symptoms after vaccination; they also emphasize that current evidence does not show a major safety signal for these rare neurologic events with Moderna’s mRNA vaccine but that rare adverse events will surface only through large‑scale monitoring [3] [10] [17]. For people who develop new neurologic symptoms after vaccination, experts advise prompt medical evaluation and reporting [18] [19].
Limitations: this summary draws only on the provided articles and surveillance summaries; available sources do not provide a single definitive incidence rate for each event after Moderna across all populations and years, and causality is explicitly not established by case reports alone (not found in current reporting).